Halia Therapeutics Strengthens Leadership and Clinical Operations Team

LEHI, Utah, Jan. 6, 2025 /PRNewswire/ -- Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, is pleased to announce key leadership additions and promotion to further its mission....

Halia Therapeutics to Present Promising Data at Obesity Week 2024

HT-6184 Shows Enhanced and Sustained Weight Loss with GLP-1 Agonist Combination for Obesity LEHI, Utah, October 31, 2024 /PRNewswire/—Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic...

Halia Therapeutics to Attend Global Health Exhibition 2024

Halia Therapeutics will showcase its LRRK2 and NEK7 inhibitors targeting Alzheimer's disease and obesity.  LEHI, Utah, Oct. 21, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments...

Venture Capital Podcast Reveals Its Founder 100 for Utah

NEWS PROVIDED BY Venture Capital PodcastJun 13, 2024, 00:35 ET -- The 2024 list celebrates the top 100 founders driving innovation and growth in the Utah community -- LEHI, Utah, June 13, 2024 /PRNewswire/ -- Today, the Venture Capital Podcast...

Halia Therapeutics to Present at Asia BIO 2024

*Presentation to be held on Wednesday, April 24, from 2:00 – 2:15 p.m. SGT LEHI, Utah, April 17, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat...